Glenmark Pharmaceuticals has filed an application in Netherlands for human trials on its molecule ‘GRC 17536’, which aims to treat pain and respiratory disorders. The company has completed animal trials on its novel chemical entity (NCE) GRC 17536 and has filed the Phase I application for first-in-man trial in Netherlands, Glenmark Pharmaceuticals.
The total market for asthma and chronic lung disease is about $30 billion and for osteoarthritis and neuropathic pain, it is nearly $10 billion. There is a huge unmet medical need in both therapeutic areas globally. crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: